Xenon Pharmaceuticals Inc.

Biotechnology • Healthcare • Burnaby, BC, United States • XENE (NGM)

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

604 484 3300 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 - Investing.com

Investing.com • Jan 5

Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative

Quiver Quantitative • Jan 5

Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha

Seeking Alpha • Dec 18

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High - Time to Buy? - MarketBeat

MarketBeat • Jan 5

Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance

Yahoo Finance • Dec 7

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Xenon Pharmaceuticals Inc. had layoffs?

No layoff events have been recorded for Xenon Pharmaceuticals Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Xenon Pharmaceuticals Inc. have?

Xenon Pharmaceuticals Inc. has approximately 316 employees.

What industry is Xenon Pharmaceuticals Inc. in?

Xenon Pharmaceuticals Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Xenon Pharmaceuticals Inc. a publicly traded company?

Yes, Xenon Pharmaceuticals Inc. is publicly traded under the ticker symbol XENE on the NGM. The company has a market capitalization of approximately $3.47 billion.

Where is Xenon Pharmaceuticals Inc. headquartered?

Xenon Pharmaceuticals Inc. is headquartered in Burnaby, BC, United States at 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.